Last reviewed 2026-04-22 · How we verify

Aflibercept-mFOLFIRI3

Aflibercept-mFOLFIRI3 is a combination regimen that pairs aflibercept (a VEGF trap) with modified FOLFIRI chemotherapy to inhibit angiogenesis while delivering cytotoxic chemotherapy.

Aflibercept-mFOLFIRI3 is a combination regimen that pairs aflibercept (a VEGF trap) with modified FOLFIRI chemotherapy to inhibit angiogenesis while delivering cytotoxic chemotherapy. Used for Metastatic colorectal cancer (in combination with mFOLFIRI chemotherapy).

At a glance

Mechanism of action

Aflibercept is a recombinant fusion protein that acts as a VEGF trap, sequestering vascular endothelial growth factor and preventing tumor angiogenesis. When combined with mFOLFIRI (a modified regimen of 5-fluorouracil, leucovorin, and irinotecan), the regimen delivers both anti-angiogenic and direct cytotoxic effects against cancer cells. This combination approach targets both the tumor vasculature and the malignant cells themselves.

Approved indications

• Metastatic colorectal cancer (in combination with mFOLFIRI chemotherapy)

Common side effects

• Neutropenia
• Diarrhea
• Fatigue
• Neuropathy
• Hypertension
• Proteinuria

Key clinical trials

• TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Aflibercept-mFOLFIRI3 CI brief — competitive landscape report
• Aflibercept-mFOLFIRI3 updates RSS · CI watch RSS
• Hôpital Franco-Britannique-Fondation Cognacq-Jay portfolio CI